Laboratorios Farmaceuticos Rovi, S.A. (LON:0ILL)

Market Cap	2.48B
Revenue (ttm)	642.04M
Net Income (ttm)	117.14M
Shares Out	n/a
EPS (ttm)	2.29
PE Ratio	21.19
Forward PE	20.62
Dividend	0.75 (1.35%)
Ex-Dividend Date	Jul 8, 2024

Volume	17,601
Average Volume	9,669
Open	55.70
Previous Close	54.85
Day's Range	54.80 - 56.75
52-Week Range	45.58 - 89.55
Beta	0.44
RSI	61.92
Earnings Date	Jul 24, 2025

About LON:0ILL

Laboratorios Farmaceuticos Rovi, S.A. manufactures, sells, and markets pharmaceutical products in Spain, European Union, OECD countries, and internationally. The company offers prescription products, including Ameride, Bertanel, Bluxam, Enoxaparin Rovi, Calcium Vitamine D3 Rovi, Exxiv, Prinvil, Rhodogil, Glufan, Hibor, Hirobriz Breezhaler, Neparvis, Medicebran, Medikinet, Mysimba, Orvatez, Tryptizol, Ulunar Breezhaler, and Volutsa. It also provides hospital products, such as Iomeron and Iopamiro, Multihance and Y Prohance, Sonovue, Empowercta+,...

• Industry: Medical - Pharmaceuticals
• Sector: Healthcare
• Founded: 1946
• Employees: 2,197
• Stock Exchange: London Stock Exchange
• Ticker Symbol: 0ILL

Financial Performance

In 2024, LON:0ILL's revenue was 763.75 million, a decrease of -7.93% compared to the previous year's 829.51 million. Earnings were 136.88 million, a decrease of -19.64%.

Financial numbers in EUR